The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Challenges that remain regarding the use of cfDNA for MRD detection in myeloma: cost and sensitivity
Dory Abelman, PhD(c), Princess Margaret Cancer Centre, Toronto, Canada, discusses the key challenges in using circulating cell-free DNA (cfDNA) for measurable residual disease (MRD) detection in multiple myeloma (MM), highlighting the high cost of sequencing and bioinformatics and the need for improved sensitivity to distinguish between benign mutations and those associated with malignancy. Efforts to enhance sensitivity accuracy include analyzing nucleosome accessibility and DNA fragment length, which may refine MRD-guided treatment strategies and improve patient outcomes. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
